This inventor holds 12 USPTO granted patents, plus 1 CIPO patent and 8 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Ucbbiopharma Srl, Astex Therapeutics Limited, Cancer Research Technology Limited. Active years: 2009-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Maidenhead, GB (2013 - 2014)
- Slough, GB (2009 - 2022)
Company Filing History:
7 out of 132 
3 out of 126 
1 out of 269 
Years Active: 2009-2026
Areas of Expertise:
Title: Richard David Taylor: Innovator in Antimalarial and Immune Modulation Research
Introduction
Richard David Taylor is a notable inventor based in Slough, GB, with a robust portfolio comprising 9 patents. His innovative work primarily focuses on pharmaceutical agents that target significant health issues such as malaria and inflammatory disorders.
Latest Patents
His latest patents include groundbreaking contributions to antimalarial treatments. One notable patent involves antimalarial hexahydropyrimidine analogues. This application concerns a series of 2-imino-6-methylhexahydropyrimidin-4-one derivatives and 3-imino-5-methyl-1,2,4-thiadiazinane 1,1-dioxide derivatives. These compounds are significant as potent inhibitors of the malaria parasite's growth and propagation in human blood, showcasing their potential as effective pharmaceutical agents.
In addition to his work on malaria, Taylor has developed fused imidazole derivatives as IL-17 modulators. This patent relates to a series of substituted fused bicyclic imidazole derivatives, including benzimidazole derivatives. These compounds are recognized for their potential benefits in treating and preventing various ailments, particularly inflammatory and autoimmune disorders.
Career Highlights
Throughout his career, Richard David Taylor has made remarkable strides in pharmaceutical innovation. He has contributed to highly specialized research aimed at developing treatments for pressing health concerns. His work ensures that he remains a pivotal figure in the fields of medicinal chemistry and drug development.
Collaborations
Taylor has collaborated with esteemed colleagues, including Zhaoning Zhu and Adrian Liam Gill. His partnerships with these talented individuals reflect a commitment to advancing scientific knowledge and bringing innovative treatments to market.
Conclusion
With a strong focus on pharmaceutical innovation, Richard David Taylor continues to contribute invaluable research toward the development of compounds that address severe health challenges, particularly in malaria and autoimmune conditions. His ongoing work and collaborations signify a dedicated effort to improve global health outcomes through innovative solutions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile